NASDAQ: JANX - Janux Therapeutics, Inc.

Yield per half year: -41.41%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Janux Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

more details
The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-06-11
ISIN US47103J1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.januxrx.com
Цена ао 30.12
Change price per day: 0% (28.95)
Change price per week: +21.69% (23.79)
Change price per month: -5.64% (30.68)
Change price per 3 month: -36.16% (45.35)
Change price per half year: -41.41% (49.41)
Change price per year: -42.73% (50.55)
Change price per 3 year: +105.9% (14.06)
Change price per year to date: -48.99% (56.75)
All parameters

Underestimation

Title Value Grade
P/S 271.8 1
P/BV 2.81 6
P/E 0 0
EV/EBITDA -24.99 0
Total: 1.5

Efficiency

Title Value Grade
ROA, % -9.57 0
ROE, % -10.09 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2329 10
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % 2686.32 10
Yield Ebitda, % 1397.68 10
Yield EPS, % 204.67 10
Total: 10
More

Institutions Volume Share, %
RA Capital Management, L.P. 9165652 17.74
FMR, LLC 4671213 9.04
BVF Inc. 4579818 8.87
Orbimed Advisors LLC. 3317927 6.42
Citadel Advisors Llc 3120205 6.04
Janus Henderson Group PLC 1931477 3.74
Blackrock Inc. 1762101 3.41
Adage Capital Partners GP L.L.C. 1355475 2.62
Vanguard Group Inc 979483 1.9
Geode Capital Management, LLC 408190 0.79

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.25252 426.34 0.8416
Principal Healthcare Innovators ETF 0.25252 618.5 0.8416
0.25522.420.84



Head Job title Payment Year of birth
Dr. David Alan Campbell Ph.D. President, CEO & Director 1.04M 1960 (65 years)
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 723k 1965 (60 years)
Mr. Charles M. Winter Chief Technical Officer 590.4k 1969 (56 years)
Mr. James Pennington General Counsel N/A
Ms. Brenda Van Vreeswyk Head of Human Resources N/A
Mr. Andy Hollman Meyer Chief Business Officer N/A 1984 (41 year)
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer N/A 1986 (39 years)
Mr. Matt Whitmire Vice President of Finance
Ms. Maria Dobek Principal Accounting Officer & VP of Accounting 1989 (36 years)

Address: United States, La Jolla. CA, 11099 North Torrey Pines Road - open in Google maps, open in Yandex maps
Website: https://www.januxrx.com